MA-RHINOSTICS/LVL
Rhinostics Inc. is excited to announce an expanded partnership with LVL technologies GmbH, which includes Rhinostics’ reselling of LVL’s decapper instrument and LVL’s distribution of Rhinostics’ automated collection devices in Germany and Austria. By combining the Rhinostics’ sample collection device ingenuity with decapper technology, laboratories can benefit from an instantly scalable automated swab and small volume blood collection processing workflow. Automation breaks through manual bottlenecks during capping and recapping steps so that laboratories can increase throughput and consistency while also decreasing cumbersome steps as well as reagent and labor costs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005373/en/
Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows (Photo: Business Wire)
“Today, researchers, clinicians, and patients alike expect more when it comes to sample collection and diagnostic workflows from respiratory pathogens, sexually transmitted infections, genetic testing to cancer biomarkers and much more,” explained Cheri Walker, PhD, President and CEO of Rhinostics. “We’re excited to expand our partnership with LVL, our supplier of high-quality collection tubes to Rhinostics during the pandemic and beyond. The companies have enjoyed a close relationship, and we can now offer a full solution for our customers by launching a customized version of LVL’s robust decapper instrument to the market.”
“We are extremely pleased to expand our partnership with Rhinostics,” said Martin von Lueder, Chief Executive Officer of LVL. “We have watched Rhinostics bring industry changing, purpose-built sample collection devices that are automation-enabled to the market. The LVL decapper instrument is the perfect complement to their consumables, allowing improvements to inefficient swab and blood collection workflows. Additionally, we look forward to offering the Rhinostics products to our customers.”
As part of the partnership, the RHINObot™ has been optimized for use with the RHINOstic® Automated Swab – a patent-pending sample collection device that integrates a unique polypropylene-based swab with an automatable cap.
Nasal, buccal, or vaginal samples may be comfortably collected in a clinical setting or easily self-collected as part of an at-home test kit. After collection, the swab is securely screwed into a small, barcoded transport tube. This transport tube may be shipped without use of viral transport or other media to reduce reagent costs as well as risks of leaking, accidental biohazard exposure, and potential PCR interference due to VTM or other media components. Dry shipment also enables greater sample concentrations to boost confidence in sensitive PCR, next generation sequencing (NGS), ELISA methods, even at very low pathogen levels.
Once in the laboratory, samples may be loaded onto the RHINObot™ for automated decapping and capping of up to 96 samples in less than 1 minute. This hands-free workflow eliminates user variability and reduces labor time by up to 80+% to significantly decrease per-test costs.
The collaborative agreement will include co-promoting the RHINOstic® and RHINObot™ solution along with marketing and educational initiatives aimed at making customers aware of the increased convenience, speed, and consistency of the automated workflow.
About Rhinostics
Rhinostics is at the forefront of revolutionizing sample collection. As a spin-out company from Harvard University and Wyss Institute, we are taking a radical new approach to sample collection device design and function. COVID-19 cast light on the urgent need to improve laboratory workflows. Rhinostics was born to meet the moment. Our united mission is to revolutionize laboratory workflows, one purpose-built collection device at a time. We improve sample collection comfort and performance while bringing efficiencies to the laboratory to remove costs and save time compared to traditional sample collection intake. Our groundbreaking technologies include functional design, novel materials, and automation solutions for removing caps and rapid accessioning for hands-free workflows. This enables robust high-throughput assays from start to finish with minimal human intervention, saving time and reducing costs.
Rhinostics’ initial product, the RHINOstic® Automated Swab, aids testing broad diagnostic and life science workflows, in areas like respiratory disease, genomics, STDs, forensics and much more. The company continues to innovate, launching a novel small-volume blood collection device, the VERIstic™, and developing a pipeline of novel sample collection devices that are purpose-built for their application combined with automation enablement. To learn more, visit https://www.rhinostics.com.
About LVL
LVL technologies is a leading global manufacturer of 2D coded tubes in the automation-friendly SBS format, including the necessary technical infrastructure. Based in Crailsheim, Germany, the company supplies organizations and companies in more than 50 countries with high-quality storage tubes for demanding long-term sample storage. Applications range from clinical and veterinary diagnostics and biobanking to compound management and research applications in biotechnology. The latest technical development is the fully automatic TLM 864 Tube Laser Marker.
To learn more, visit https://www.lvl-technologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005373/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom